NextCure Inc. has announced updates on its two antibody drug conjugate $(ADC)$ programs. For SIM0505, a CDH6-targeted ADC, data from the Phase 1 dose escalation study are anticipated to be presented in the second quarter of 2026. The study is evaluating SIM0505 in patients with advanced solid tumors, with a focus on gynecological cancers and platinum-resistant ovarian cancer. For LNCB74, a B7-H4-targeted ADC, dosing has commenced in higher dose cohorts in an ongoing Phase 1 dose escalation study following a recent protocol amendment. Proof-of-concept data for LNCB74, previously expected in the first half of 2026, has been delayed, and a trial progress update is now anticipated in the second half of 2026. No clinical study results have been presented to date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-006021), on January 23, 2026, and is solely responsible for the information contained therein.